Naturhouse Health, S.A. Stocks

2.53Last Updated 24.04.2026

Issuer Rating

4/7
Performance

Favourable

Risk

Considerable

Recommendation

Hold

Market Cap

€ 182.71M

Buy
Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
2.53
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Excellent dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Naturhouse Health, S.A. operates in the nutrition and weight management industry in Spain, Italy, France, Poland, and internationally. The company sells food supplements that are made from natural extracts to facilitate the consumption of various nutrients; and foods and drinks, such as diet products for breakfast, snacks, and meal substitutes. It also offers cosmetics and body care products, including beauty products related to skincare during the slimming process comprising cellulite, firming products, etc.; and anti-ageing products. As of December 31, 2020, it operated through a network of 1,788 centers in 28 countries. The company sells its products through directly operated and franchised Naturhouse centers. The company was formerly known as Housediet, S.L.U. The company was founded in 1991 and is based in Madrid, Spain.

Company Valuation

Slightly overvalued
3/7

From both historical and forecast perspectives, the stock is slightly overpriced compared to similar stocks. Specifically, the stock is fairly valued on P/E, neutral on E

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis
X-channel

Buy

Sell

0 more stocks